OGN - Organon & Co.
Organon and Co. (NYSE: OGN - Get Free Report) reached a new 52-week high during trading on Tuesday. The stock traded as high as $13.76 and last traded at $13.7540, with a volume of 4583387 shares trading hands. The stock had previously closed at $13.75. Analyst Ratings Changes Several research firms have recently weighed in
VANCOUVER, BC / ACCESS Newswire / August 20, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce it has acquired a 2% Net Smelter Return ("NSR") royalty (the "Royalty") on the Haldane silver project in Yukon Territory, Canada. Haldane Royalty Highlights 1,2,3,4 Haldane is a high-grade silver project owned by Silver North Resources Ltd.
VANCOUVER, BC / ACCESS Newswire / August 17, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce the formation of a generative exploration alliance (the "Alliance") with a subsidiary of Aurum Discovery ("Aurum"), a private prospect generator based in Ireland. The Alliance will focus on generating gold and silver targets in prospective mineral belts within Norway.
California State Teachers Retirement System lifted its holdings in Organon and Co. (NYSE: OGN) by 34.8% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 327,075 shares of the company's stock after acquiring an additional 84,497 shares during the period.
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced the MIUD
JERSEY CITY, N.J.--(BUSINESS WIRE)--HCPs, healthcare settings and pharmacies can begin REMS certification for Organon's hormone-free copper IUD, MIUDELLA, ahead of upcoming launch.
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Organon (OGN) came out with quarterly earnings of $0.85 per share, missing the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $1 per share a year ago.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the company's Board of Directors declared a quarterly dividend of $0.02 for each issued and outstanding share of the company's common stock. The dividend is payable on September 10, 2026, to stockholders of record at the close of business on August 14, 2026. About Organon Organon (NYSE: OGN) is a global h.
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
VANCOUVER, BC / ACCESS Newswire / July 27, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties for the first half of 2026 and forecast for the remainder of the year. Highlights Approximately 44,000 metres of partner-funded drilling completed or underway on seven exploration stage projects where Orogen holds various royalty interests Over 7,000 metres of conversion drilling completed at Ermitano's Navidad/Winter deposit, where Orogen holds a cash-flowing 2% net smelter return ("NSR") royalty Received $1.72 million from the sale of projects and payments from exploration partners year to date Two new royalties created from project sales New pipeline of projects generated from partner-funded gold exploration in Nevada and Utah, and from Orogen's internally funded programs Additional six drill programs with 25,000 metres of drilling estimated in H2-2026 Paddy Nicol, CEO of Orogen, commented, "Orogen's strategy is built on a scalable business model of profitably generating highly prospective exploration stage mineral projects and advancing them through strategic partnerships, while retaining royalties.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Presents VTAMA (tapinarof) cream, 1% Analysis of Phase3 Pooled Data Showing Early Consistent Improvements in Eczema Patients Across Age Groups.
Shareholders of Organon & Co. NYSE: OGN approved the company's proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting held Wednesday, according to preliminary voting results announced during the meeting.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its second quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission (“SEC”). The company also plans to disclose certain non-GAAP financial measures and their reconciliation to their comparable GAAP measures for the second quarter 2026, which will.
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Orogen Royalties Inc. (TSXV:OGN)(OTCQX:OGNNF) ("Orogen" or the "Company") is pleased to announce its shares have been qualified to begin trading on the OTCQX®Best Market ("OTCQX"). Orogen has upgraded to OTCQX from the OTCQB® Venture Market.
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Are TBRG, OGN, MDV Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propo
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Organon & Co. (NYSE: OGN) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Organon will receive $14.00 in cash for each share of Organon that they own. KSF is seeking to determine whether this consideration and the process that led to it.